9.17

3.38% 0.30

After Hours: 9.18 0.010 +0.11%

Ginkgo Bioworks Holdings Inc (DNA)

Overview News Price History Option Chain Why DNA Down? Discussions Forecast

Ginkgo Bioworks Holdings Inc stock is traded at $9.17, with a volume of 1.31M. It is up +3.38% in the last 24 hours and down -0.86% over the past month. Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Previous Close:

$8.87

Open:

$8.87

24h Volume:

1.31M

Relative Volume:

1.05

Market Cap:

$555.61M

Revenue:

$217.11M

Net Income/Loss:

$-651.19M

P/E Ratio:

-0.7059

EPS:

-12.99

Net Cash Flow:

$-387.26M

1W Performance:

+12.52%

1M Performance:

-0.86%

6M Performance:

-27.91%

1Y Performance:

-21.29%

1-Day Range:

$8.87

$9.38

1-Week Range:

$8.08

$9.38

52-Week Range:

$5.00

$17.58

Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile

Name

Ginkgo Bioworks Holdings Inc

Sector

Healthcare (1115)

Industry

Biotechnology (624)

Phone

(877) 442-5362

Address

27 DRYDOCK AVENUE, BOSTON

Employee

834

Twitter

Next Earnings Date

2024-08-08

Latest SEC Filings

DNA's Discussions on Twitter

Compare DNA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DNA Ginkgo Bioworks Holdings Inc	9.17	537.44M	217.11M	-651.19M	-387.26M	-12.99
VRTX Vertex Pharmaceuticals Inc	468.38	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.54	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	406.40	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.74	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.07	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-15-24	Downgrade	BTIG Research	Neutral → Sell
May-10-24	Downgrade	William Blair	Mkt Perform → Underperform
Nov-14-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-09-23	Downgrade	BTIG Research	Buy → Neutral
Jun-02-23	Downgrade	Goldman	Neutral → Sell
May-11-23	Downgrade	William Blair	Outperform → Mkt Perform
Nov-29-22	Initiated	Berenberg	Buy
Oct-04-22	Initiated	Morgan Stanley	Equal-Weight
May-18-22	Downgrade	BofA Securities	Neutral → Underperform
Mar-02-22	Resumed	Cowen	Outperform
Feb-23-22	Initiated	Goldman	Neutral
Feb-01-22	Initiated	BofA Securities	Neutral
Jan-28-22	Initiated	BofA Securities	Buy
Jan-07-22	Initiated	BTIG Research	Buy
Nov-29-21	Initiated	Jefferies	Buy
Oct-13-21	Initiated	Raymond James	Outperform
Oct-12-21	Initiated	William Blair	Outperform
Sep-20-21	Initiated	HSBC Securities	Buy

View All

Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News

Jan 03, 2026

Ginkgo Bioworks (DNA) Upgraded to Strong Buy: Here's What You Should Know - MSN

Jan 03, 2026

Ginkgo Bioworks announces COO transition and operational leadership changes By Investing.com - Investing.com Australia

Jan 03, 2026

Ginkgo Bioworks announces COO transition and operational leadership changes - Investing.com

Jan 03, 2026

Jan 02, 2026

Is Ginkgo Bioworks Holdings Inc a good long term investmentInsider Trading Compliance & Affordable Trading Techniques - earlytimes.in

Jan 02, 2026

Penny Stocks That Will Make You Richcareer Html Definition Characteristics & How To Invest - shababeek.org

Jan 02, 2026

Jan 01, 2026